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ABSTRACT
Evidence-Based Strategies for Treatment and
Referral of Chronic Pain in Primary Care
Morgan Ann Bateman
College of Nursing, BYU
Master of Science
Chronic pain is an ever present issue in the United States, with more people suffering
from it than heart disease, cancer, and diabetes combined. Chronic pain is the most frequent
complaint in primary care, and it poses significant challenges to both primary care providers
(PCPs) and their patients. At the root of many of these challenges is the prescription and
management of opioid prescription drugs used to treat chronic pain. Opiate misuse, abuse, and
diversion are serious risks of opiate prescribing. Risk assessment tools are available to aid the
PCP in determining the severity of risk for potential patient abuse, and include the Revised
Screener and Opioid Assessment for Patients with Pain (SOAPP-R), the Opioid Risk Tool
(ORT), and the Brief Risk Questionnaire (BRQ). Patients who score “high” on these scales
should be referred to pain specialty clinics; however, it is often necessary to manage these
patients in the primary care setting. The CDC Guidelines for Prescribing Opioids for Chronic
Pain—United States, 2016 serves as a protocol for prescribing opiate medications for chronic
pain. Inherit in these guidelines is the utilization of urine drug testing and patient provider
agreements, which although underutilized, have shown to improve patient and PCP outcomes.
Such outcomes for the PCP include improved efficiency and time-management in the clinic,
more accurate detection of medication adherence and possible diversion, and improved
objectivity with prescribing decision-making. The outcomes for patients include reduced
aberrant drug behaviors, which results in improved patient safety. This paper will address
evidence-based strategies for PCPs to aid them in appropriate referral processes and provide
guidelines for safe and effective prescription of opioid medication for patients with chronic pain.
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Evidence-Based Strategies for Treatment and
Referral of Chronic Pain in Primary Care
One in ten Americans suffer from chronic pain (Dennis, 2015); in fact, more people
suffer from chronic pain than from cancer, heart disease, and diabetes combined (National
Institute of Health [NIH], 2013). Consequently, chronic pain is the most common complaint of
patients in primary care (Matthias et al., 2010). Chronic pain is multifaceted, as evidenced by its
various definitions. One definition describes chronic pain as persistent pain that is unresponsive
to routine pain treatments (Leverence et al., 2011). Another definition explains it as pain
associated with chronic pathologic processes that cause pain for months or years (Leverence et
al., 2011). Regardless of the definition, chronic pain is an ever-present issue across the nation. It
is estimated that the direct and indirect expenditures of chronic pain cost Americans $635 billion
annually (Gaskin & Richard, 2012). Along with its high prevalence and financial strain, chronic
pain presents a variety of other challenges for the primary care provider (PCP).
The challenges of treating chronic pain in primary care exist ubiquitously across the
nation. PCPs describe treating patients with chronic pain as “frustrating,” “overwhelming,” and
“ungratifying” (Matthias et al., 2010, p. 1692). Nearly 80% of PCPs in one study agreed that
pain management is a “burden” to their practice. Patients experiencing chronic pain also express
concerns about treatment they receive in primary care with over 40% reporting suboptimal or
unsuccessful control of pain (Leverence et al., 2011).
Prescription and management of opioid medications are at the root of many PCPs’
concerns regarding treatment of patients with chronic pain. Since 1999, sales of hydrocodone
and oxycodone have quadrupled in the U.S. Only 4% of the world’s population reside in the
United States, yet 80% of the world’s opioid use occurs in the U.S. (Centers for Disease Control
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and Prevention [CDC], 2016). In addition to the barriers mentioned above, PCPs encounter other
obstacles, including lack of standard tools to assess opioid use, fears of regulatory agencies,
interactions with hostile patients, feeling pressured to prescribe opioids to patients, and the risks
of diversion and overdose (Matthias et al., 2010).
Diversion occurs when a provider prescribes a medication to a patient, who then turns the
medication over to another person for illegal use (National Conference of Commissioners on
Uniform State Laws, 1994). In fact, 70% of physicians reported that they had a patient divert
opioids, and 33% of patients prescribed opioids had a life-threatening event due to opioid use
(Leverence et al., 2011). A possible solution to detecting diversion is urine drug testing—if
presence of the opioid is not found in the patient’s urine drug screen, this is highly indicative of
diversion. As patients misuse and divert opioids, the consequences for their safety could be dire;
as such, PCPs have an essential responsibility to assess patient needs accurately and prescribe
opioid medications judiciously.
Without specific tools, it is not always easy to predict which patients might misuse
opiates. Patients who misuse opiates “crush every stereotype,” indicating vast differences in the
misusing population—young, old, pregnant, healthy, chronically ill, homeless, multigenerational
family, etc. (Binswanger & Gordon, 2016, p. 2). The unpredictability of so-called common
stereotypes associated with opiate misuse highlights the importance of implementing risk
assessment with standardized assessment tools. However, many PCPs report a lack of knowledge
about implementation of standardized risk assessment tools and rely on “general impressions of
risk” or a “gut feeling” to identify patients who may misuse opioids (Krebs et al., 2014, p. 1153).
Due to the challenges of assessing potential opiate misuse, many PCPs prefer to refer
their chronic pain patients to pain management clinics. Specialized pain clinics, however, are not
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always readily available (Matthias et al., 2010). As a result, many PCPs manage patients with
chronic pain (St. Marie, 2016). Treatment of chronic pain patients by PCPs may not be the best
choice for some patients. PCPs are constrained by short appointments that do not provide
adequate face-to-face time with patients and often have infrequent follow-up appointments
resulting in delayed care (Krebs et al., 2014). As one physician stated, “These are complex
patients with multiple problems…” and “… lack of time for important opioid prescribing
decisions could lead to serious consequences” (Krebs et al., 2014, p. 1152).
Treatment of chronic pain is a challenge fraught with frustration for both PCPs and
patients. PCPs need to learn and act on established principles of safety and best practice when
treating patients with chronic pain. Therefore, the purpose of this paper is to provide evidencebased strategies for PCPs to aid them in appropriate referral processes and provide guidelines for
safe prescription of opioid medication for patients with chronic pain. Important aspects of
chronic pain management discussed in this paper include risk assessment for opiate misuse,
guidelines for referral of a patient with chronic pain, the CDC Guidelines for Prescribing Opioids
for Chronic Pain, urine drug testing (UDT), and patient-provider agreements (PPAs).
Risk Assessment for Opiate Misuse
One of the main concerns in treating patients with chronic pain is the potential for misuse
of opioids. PCPs traditionally rely on patient history and previous patient interactions to
determine patients who may misuse opioids. As a result, PCPs often underestimate their patients’
potential to misuse opioids. An objective, standardized, risk assessment tool should, therefore, be
the starting point for treating any patient presenting to primary care with chronic pain. While no
single opioid risk predictor tool is validated across all populations to predict aberrant behavior,
the risk factors addressed in these tools coincide with the risk factors of opioid misuse identified
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in the literature. Risk assessments identify the patients’ potential for opiate misuse and aid the
PCP in the decision to treat or refer the patient to a pain management specialist (Dowell,
Haegerich, & Chou, 2016). Risk assessments may include but are not limited to questionnaires,
pill counts, and urine drug testing (UDT) (Setnik, Roland, Pixton, & Sommerville, 2017). There
are multiple tools available (Table 1), including the following:
1. Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R) (Butler,
Fernandez, Beniot, Budman, & Jamison, 2008),
2. Opioid Risk Tool (ORT) (Webster & Webster, 2005),
3. Pain Medication Questionnaire (PMQ) (Holmes et al., 2006),
4. Brief Risk Questionnaire (BRQ) (Jones, Lookatch, & Moore, 2015),
5. Diagnosis, Intractability, Risk, and Efficacy score (DIRE) (Jones, et al., 2015).
The SOAPP-R, ORT, and BRQ are described briefly below.
The Opioid Risk Tool (ORT)
The ORT (Table 2), a self-report tool designed for adult patients in primary care, can be
administered prior to starting opioid therapy (Webster & Webster, 2005). The tool is short,
simple and addresses five areas in which patients score themselves. The five areas included in
the ORT are (a) a family history of drug abuse (alcohol, illegal drugs, prescription drugs); (b)
personal history of drug abuse (alcohol, illegal drugs, prescription drugs); (c) age between 16 and
45 years; (d) psychological disease (attention deficit disorder, bipolar, depression, schizophrenia,
obsessive compulsive disorder); and (e) a history of preadolescent sexual abuse. The scores in
each of these categories are combined. Scores of three or less indicate a low risk for future opioid
misuse; scores of four to seven indicate moderate misuse; and scores of eight or more indicate a
high risk for future opioid misuse (Webster & Webster, 2005).
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The Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R)
Similar to the ORT, the SOAPP-R is a simple, self-questionnaire that can be completed
by patients prior to beginning opioid therapy (Table 3) (Butler et al., 2009). It entails 24
questions ranked by the patient on a 5-point Likert scale (never, seldom, sometimes, often, or
very often). The questions address habits or characteristics, such as experiencing mood swings,
smoking a cigarette within an hour of awakening, taking medication in a way other than how it is
prescribed, participating in illegal drug use in past five years, having a family history of
substance abuse, losing medications, craving medications, and having been arrested or having
legal problems. After the responses are combined, a score of less than nine indicates low risk,
with a score of 10-21 indicating moderate risk, and a score of 22 or more indicating high risk
(Butler et al., 2009).
The ORT and SOAPP-R are useful to the clinician because they take the patient less than
five and ten minutes to complete, respectively; and do not require staff to be extensively trained
or occupy the PCP’s highly valued time in clinic. However, patient honesty or accuracy is
always a concern. In a comparison study between self-report questionnaires and a clinical
interview between a health care provider and patient, a clinical interview had higher sensitivity
and improved predictive accuracy of misuse. To combat the weaknesses of self-report
questionnaires, an interview-based assessment tool, the Brief Risk Questionnaire (BRQ), was
developed (Jones et al., 2015).
The Brief Risk Questionnaire (BRQ)
The BRQ consists of 12 questions adapted from the Brief Risk Interview (BRI) (Jones et
al., 2015). The BRQ is used during a scheduled interview between the PCP and patient. The 12item questionnaire closely reflects the items addressed by the ORT and SOAPP-R. However, it
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also includes questions about the patients reading ability, need for another person to handle
medications for them, and if the patient was previously discharged by a PCP from their medical
practice. Scores are tabulated and the patient categorized into low, medium, or high-risk potential
to misuse opioids. Authors claim this tool surpasses other tools because it predicts not only the
potential for addiction, but also the potential for abuse, misuse, and diversion as well (Jones et
al., 2015). The BRQ is also beneficial because it is a more detailed assessment allowing the PCP
to use clinical judgment skills during the interview. However, its use in a busy primary care
practice may be limited, as the interview may take up to 45 minutes.
In short, there is no perfect risk assessment tool—predicting human behavior is a
challenging task (Jones et al., 2015). The PCP’s decision regarding which assessment tool to use
should be based on his or her time constraints in the clinic and individual preference. While these
tools are not perfect, they are helpful, and serve as a useful entry point for treatment of patients
with chronic pain in primary care. These tools, along with clinical judgment, can aid the PCP in
categorizing patients with chronic pain into three different opioid misuse risk strata—low-risk,
moderate-risk and high-risk and thereby help determine appropriate treatment (Kaye et al., 2017;
Kirsh & Fishman, 2011).
Treatment of Low-, Moderate-, and High-Risk Patients
Once the PCP establishes the level of risk, they are able to determine appropriate
treatment for the patient.
Low-Risk Patients
Low-risk patients are those who score less than three on the ORT, less than nine on the
SOAPP-R, or rank “low” upon completion of the BRQ. These patients typically have no personal
or family history of aberrant drug behaviors, lack behaviors associated with substance abuse, and
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lack medical or psychiatric comorbidities. These patients may be managed in primary care with
consistent monitoring using screening tools, the Centers for Disease Control (CDC) Guidelines
for Prescribing Opioids for Chronic Pain (Dowell et al., 2016), UDT, and PPAs (Cheatle,
Gallagher, & O’Brien, 2018). A routine follow-up every three months is sufficient for these
patients (Kaye et al., 2017). Low risk patients who are prescribed a low-dose, short-acting
opioid, in conjunction with other adjuvant treatments, exhibit improved function and quality of
life. A low-dose of a short-acting opioid (5 mg oxycodone or hydrocodone) is key—the higher
the opioid dose, the higher the risk of aberrant behaviors (Cheatle et al., 2018). Although
prescribed a low opiate dose, these patients still need close monitoring for atypical behavior,
because progression to moderate-risk is possible (Kirsh & Fishman, 2011).
Moderate-Risk Patients
Moderate-risk patients are those who score between a four and seven on the ORT, score
between a 10-21 on the SOAPP-R, and rank as “moderate” upon completion of the BRQ. The
patient profile for moderate-risk patients may include the following: current cigarette smoker,
personal or past family history of substance abuse disorder, and comorbid medical and or
psychological conditions (Pagé, Saidi, Ware, & Choinière, 2016). Moderate-risk patients may be
treated in primary care, but referral to a pain specialty clinic or consultation between the PCP
and a pain specialist is encouraged (Kirsh & Fishman, 2011). These patients should be evaluated
more frequently in the office—at least monthly—and use of UDT (to detect possible diversion
and/or concurrent controlled substance use) and maintaining the stipulations outlined in the PPA
should be strictly monitored (Kaye et al., 2017).
While consultation with a pain specialist for moderate risk patients is encouraged, there is
limited evidence of its usefulness. Clark et al. (2015) compared outcomes between two groups of
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patients: those who received the usual course of care and those who received the usual course of
care combined with a PCP-to-pain-specialist telephone consultation. There was no statistical
significance in reduction of pain or improvement in function between patients who had a pain
specialist consultation and those who did not. However, despite the lack of positive patient
outcomes, PCPs indicated they preferred the practice. Their reasons for supporting PCP-to-painspecialist telephone consultations indicated that telephone consultation is an easy and widely
accessible resource, which results in timely treatment for the patient and saves time and money
compared to a conventional referral. It also offers reassurance to the PCP (Clark et al., 2015). If
PCPs treat moderate-risk patients in their practices, a phone consultation may be an added
resource in addition to the implementation of the CDC Guidelines, UDT, and PPAs. Similar to
low-risk patients, the moderate-risk patient needs close monitoring, due to the possibility of
transition to a high-risk level (Kirsh & Fishman, 2011).
High Risk Patients
High-risk patients are those that score an eight or more on the ORT, score higher than a
22 on the SOAPP-R tool, and/or are classified as “high” risk on the BRQ. High-risk patients
commonly exhibit a family or personal history of addictive behavior; have coexisting psychiatric
disorders, and have a history of drug abuse and/or drug diversion. Patients are especially
complex when they have psychiatric comorbidities and a history of aberrant drug disorders and
are prescribed opioids. Many PCPs lack the effective resources and clinic time to give these
complex patients the care they need (Cheatle et al., 2018). Therefore, experts recommend that
PCPs refer high-risk patients on long-term opioid therapy to a pain specialist in a pain specialty
clinic (Kirsh & Fishman, 2011).
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Guidelines for the Referral of the Chronic Pain Patient

There are two important aspects of chronic pain referral that are important in primary
care: a thorough referral and managing patient expectations.
Quality of Referrals
High quality referrals help pain specialists prioritize patients and thereby provide high
quality care. However, in a study of 256 referrals, only 2% of referrals from PCP to pain
specialists included all of the information the pain specialists identified as important. Further,
when questioned about referrals from PCPs, a group of neurologists and pain specialist
physicians working in a large multidisciplinary outpatient clinic for back pain identified 12 items
that should be included in a referral. These items include symptom duration, use of analgesics,
alleviating and/or aggravating factors, occupational status, pain distribution, sensory symptoms,
utilized treatment, deep tendon reflexes, motor function, sensory examination, and radiculopathy
tests (Gulati et al., 2012). A referral complete with these items will enable the PCP and pain
specialist to jointly work together in establishing the correct priority and treatment for the patient
(Gulati et al., 2012).
Managing Patient Expectations of a Pain Clinic
Many patients may feel an array of emotions upon referral to a pain specialist—
disappointment, anger, frustration—as some may feel that they are being “abandoned” by their
PCP. Effective communication and teaching of pain clinic expectations may ease these feelings.
Communicating to the patient about possible treatment options and outcomes from treatment at a
pain clinic may contribute to better patient satisfaction. PCPs should emphasize that many
patients referred to pain specialty clinics report high satisfaction with their experience (Hadi,
Alldred, Briggs, Marczewski, & Closs, 2016). It may also help manage expectations if patients
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understand that the pharmacological modality most commonly employed by pain specialists is
the addition of a new drug or titration of previously established drugs. In addition, pain
specialists’ most common non-pharmacological treatment is activity management. This holistic
approach along with the generous time spent with the pain specialist at each visit and specialized
knowledge result in patients who feel like the provider listened to their needs and concerns.
Additionally, patients managed in pain specialty clinics report decreased intensity of pain and
improvement of physical functioning at three months following referral (Hadi, et al., 2016).
PCPs should share these positive patient outcomes with patients they refer to pain specialists to
help them manage their expectations and allay concerns.
Managing Patients with Chronic Pain in Primary Care
While it is preferred that patients with complex, chronic pain receive a referral to a pain
specialist, this is not always feasible. Limited availability of specialized pain management clinics
and sometimes PCP preference result in PCPs managing patients with chronic pain. In the event
that a PCP must manage chronic pain, the PCP should employ the consistent use of set protocols;
this is particularly important when treating patients with chronic pain who are on opioid therapy.
Readily available protocols include the CDC Guidelines for Prescribing Opioids for Chronic
Pain, the effective use of PPAs, and UDT.
Protocols for Managing Patients with Chronic Pain
Management of patients with chronic pain is often time consuming; hence, it is
imperative for the PCP to have a set protocol in place for all chronic pain visits. As various tasks
in a primary practice are analyzed (patient phone calls, medication refill requests, and other
issues regarding patient care), 52% of all tasks are related to chronic pain, with 21% of tasks
attributable to opioids and other controlled substances. As evidenced, treating patients with
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chronic pain takes a considerable amount of the PCP’s time. The solution is implementation of a
clear and consistent protocol for all patients with chronic pain (Khodaee & Deffenbacher, 2016).
The CDC has recognized the opioid prescription misuse problem since 2014 when it
added prevention of opioid overdose to its list of the top five public health challenges (CDC,
2014). Established guidelines to prescribing opiates in primary care are found in the CDC
Guidelines for Prescribing Opioids for Chronic Pain—United States, 2016 (Table 4). The
intended professional audience for the guidelines include PCPs in outpatient care settings
(physicians, nurse practitioners, physician assistants, and internists). Furthermore, the guidelines
are specific to the treatment of patients over age 18 years with chronic pain lasting longer than
three months that is not associated with cancer, palliative care, or end of life care (Dowell et al.,
2016). While the CDC identifies that these guidelines are voluntary, it provides grade ‘A’
evidence (high certainty the benefit is significant) for 11 out of the 12 recommendations, with
one recommendation receiving grade B evidence (high certainty the benefit is moderately
significant). Implementation of the CDC guideline improves communication between patient and
PCP about risks and benefits of long-term opiate treatment, reduces the risk of misuse and
overdose of opiate medication, and improves safety and efficacy of pain treatment (Dowell et al.,
2016).
The CDC guidelines form a foundation for treatment of patients with chronic pain. While
all 12 items of the guidelines are self-explanatory, PPAs and UDT are two practices that warrant
further exploration due to their limited use in primary care practice. Only 4-44% of primary care
practices utilize PPAs (Sekhon et al., 2013), with only 8% of patients in one universityassociated chain of clinics receiving UDT (Krebs et al., 2014). In addition to the other 10
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recommendations in the guidelines, PPAs and UDT are essential to the protocol for treatment of
chronic pain to ensure PCP protection and patient safety.
Patient Provider Agreements (PPAs)
There are many terms used to describe a PPA, which include “contract,” “treatment
agreement,” or “behavioral agreement” (Craig, 2012); however, despite the terminology used, all
PPAs serve the same purpose. A PPA is “an explicit bilateral commitment to a well-defined
course of action” (Craig, 2012, p. 511), and is an agreement in writing between the PCP and
patient that communicates the expected standards of opioid therapy compliance (Collen, 2009).
Because of its limited use in practice, as well as limited research presently available, many PCPs
may be unaware of the potential benefit and use of PPAs.
There are four parts to a PPA: statements that are specific to the practice, educational
statements, directive statements, and violation statements. Practice-specific statements are those
that are unique to the practice, such as refill procedures and goals of treatment. Educational
statements include the facts regarding opioid medication—the potential adverse effects and risks
involved. Directive statements include instructions on proper use of the opioid medications. For
example; do not combine with alcohol or illicit drugs. Finally, violation statements are those that
outline the consequences if parameters of the contract are broken (Collen, 2009).
In addition to the four areas outlined above, PPAs should also include the following five
provisions. First, patients should obtain opioid medication from only one prescriber and one
pharmacy. Second, patients may be asked for random or routine UDT. Third, office visits for
pain must occur at an established minimal interval. Fourth, the patient may be subject to pill
counts. Fifth, prescription duration may be limited (biweekly rather than monthly.) Furthermore,
a contract should serve as a form of informed consent as it outlines the risks and benefits of using
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opioid medication long term. The potential consequences of breaking the contract
(discontinuation of medication or treatment) should be explicitly stated (Craig, 2012). The
American Medical Association also outlines four requirements inherit in a PPA: (a) both patient
and the PCP have unique responsibilities; (b) the PPA is consensual, not compulsory; (c) it is a
negotiation between the PCP and patient; and (d) the consequences for breaking the contract are
stated (Craig, 2012).
Despite the limited research regarding PPAs and patient safety, the narrow volume of
literature on the topic indicates multiple benefits for both patient and prescriber. Benefits of
PPAs include improved patient safety (Sekhon et al., 2013) and improved assessment of misuse
for the PCP. While not an assessment tool itself, a PPA can aid the PCP in more accurately
assessing possible misuse when patients do not uphold the agreed-upon guidelines of the contract
(Ziegler, Compton, & Goldenbaum, 2011). The use of a PPA may contribute to better patient
safety. In a sample of 800 veterans on chronic opioid therapy, half had an opioid contract
agreement with their PCP. The use of a PPA was associated with a decreased risk of aberrant
drug behaviors; specifically, overconsumption, mixing opioids with alcohol or other drugs, and
crushing, chewing, or inhaling the opioid (Sekhon et al., 2013). A decrease in such behaviors
translates to better patient safety.
In addition to improved safety for patients who chronically use opioids, PPAs may offer
considerable benefits for the PCP. The use of a PPA enables the PCP to assess for misuse based
on the patient’s cooperation with established guidelines of the PPA. For example, patient
behaviors, such as using more than one prescriber, frequently losing their prescribed opiate, or
running out of their prescribed opiate early are behaviors that violate agreements in the PPA and
indicate the potential for misuse (Ziegler, et al., 2011). In this sense, the PPA serves as a tool for
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PCPs to assess for risk potential in their patients. Additionally, the PPA is a written consent in
which patients acknowledge the risks of opioid therapy, which gives the PCP a sense of security.
Some predict that PPAs will become a standard of care in the near future as governmental
agencies aim to reduce opioid risk and misuse (Craig, 2012).
Urine Drug Tests
A stipulation regarding either random or routine UDT is an important component of the
PPA. The use of UDT should not be underestimated, as it is recommended by nine of the ten
most recent prescribing guidelines pertaining to opioids and chronic pain (Bauer, Hitchner,
Harrison, Gerstenberger, & Steiger, 2016). Further, the CDC recommends UDT for all patients
receiving long-term opioid prescriptions (Table 4, item 10). The consistent use of UDT for all
patients on chronic opioid therapy serves multiple purposes: it aids in efficiency and time
management in the clinic; it serves to monitor medication adherence; it helps to detect opioid
diversion; and it assists to prevent PCP stereotypical thinking from patient to patient (Bauer et
al., 2016).
The UDT serves as a useful tool to distinguish substance use disorders in their earliest
stages (Krebs et al., 2014). Notwithstanding the lack of evidence regarding the usefulness of
UDT in opioid overdoses, the UDT is a form of laboratory testing for medication monitoring.
For example, PCPs order recurrent creatinine testing for their patients taking diuretics in order to
protect them from potential harms of the drug. UDT with long-term opioid prescribing should be
no different—laboratory monitoring serves as a way to detect substance misuse behaviors that
may place patients at risk for potential adverse events (Krebs et al., 2014).
The results of the UDT will indicate to the PCP possible substance use disorder and/or
diversion. The UDT is a qualitative test that can only screen for the presence (not the amount) of
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illegal substances, alcohol, and other prescribed controlled substances not reported by the
patient. Additionally, a negative result for the prescribed opioid is highly indicative of diversion
(Sekhon, 2013). To highlight this, in a study of 800 Veterans Affairs patients prescribed opioids
for at least three months, 19.5% of patients tested positive for an illegal substance or an
unreported opioid, and 25.2% of patients had negative UDT results for their prescribed opioid.
Furthermore, among PCPs caring for patients with abnormal UDTs, only 28% of PCPs had
documentation showing that they had addressed the abnormal UDT by stopping the opioid or
even discussing the abnormal result with the patient (Sekhon, 2013). In short, UDT is essential
for determining medication adherence and/or diversion. Additionally, it serves as a form of
protection to PCPs, as they document their actions and medical decision making as it pertains to
UDT and opioid prescribing.
As the PCP consistently utilizes both random and intermittent UDT for all patients on
long-term opioids, it will help prevent stereotypical thinking that may lead to UDT only certain
groups of patients. For example, Black patients received UDT twice as often as white patients
did; however, evidence indicates that Black patients are less likely to misuse opioids and have a
lower overdose rate when compared with White patients (Bauer et al., 2016). Other factors found
to contribute to increased likelihood of random UDT included patients on Medicaid, patients
with substance abuse disorder or history, and patients prescribed higher dosages of narcotic.
While the latter two are indicative of potential for abuse, the PCP should not rely solely on these
as indications to guide their UDT decisions. Conversely, patients with hypertension, or obesity,
or those with a non-local addresses were selected the least amount for random UDT (Bauer et al.,
2016).
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PCPs need to make it a priority to educate patients regarding the non-discriminatory
practice of and importance of UDT. One patient stated, “It kind of made me feel like I was doing
something wrong, which I wasn’t, but I signed a contract… and I follow that contract to the letter
because I know what it’s like to not have the meds” (Krebs et al., 2014. p. 1152). With
education, patients can understand how UDT relates to their safety. This patient further stated,
“They asked me if I would urinate in a cup. I felt fine with that. I do not feel like they can do
their job if I lie to them, and this way they know whether I lied to them or not. So I feel a lot
safer” (Krebs et al., p. 1152). By helping patients understand this point of view, PCPs have an
opportunity to reframe their patients’ viewpoint about the use of UDT as a standardized tool for
all patients on long-term opioids. In so doing, patient safety will be enhanced and PCPs will be
able to implement an efficient form of monitoring that protects their prescribing power (Krebs et.
al, 2014).
Conclusion
Chronic pain is a serious issue in primary care resulting in multiple challenges for the
PCP. PCPs may choose to treat chronic patients in their primary care practice or refer them to a
pain management specialty if available. A detailed, thorough referral to pain management aids in
PCP communication and patient outcomes. Additionally, communicating to the patient about
expectations of pain management improves patient outcomes. When referral to pain specialists is
not feasible, there are many tools available to aid the PCP in treating chronic pain patients in
practice. These include risk assessment tools, the CDC Guidelines for opioid prescribing, UDT,
and PPAs. These tools help the PCP safely prescribe opioid medications; which in turn, provides
improved safety and outcomes for the patient.
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Table 1.
Opioid Risk Screening Tools and Tested Populations
Opioid Risk Screening Tool
SOAPP-R

Opioid Risk Tool (ORT)

Pain Medication Questionnaire (PMQ)

Brief Risk Questionnaire (BRQ)

Diagnosis, Intractability, Risk and Efficacy
Score (DIRE)

Tested Population
1. Original validation study (2008), n=
207, patients selected from 3 states
(MA, OH, and PA). All patients were
on chronic opioids for noncancer
pain.
2. Cross-validation study (2009) n= 221,
and patients were selected from 5
states (IN, MA, NH, OH, and PA).
These patients were all being treated
for noncancer pain (Finkelman et al.,
2015).
1. Preliminary validation study (2005), n=
135, patients were referred to the
author’s pain clinic from January 2000
to May 2001 (Webster & Webster,
2005).
1. Original validation study (2004), n=
184, newly evaluated patients at a
pain center in Dallas, Texas who were
seen between October 2001 and May
2002 (Adams et al., 2004).
2. Additional validation study (2009), n=
1,540, heterogeneous sample of
chronic pain patients at an
interdisciplinary pain clinic (Buelow,
Haggard, & Gatchel, 2009).
1. Validation study (2015), n= 299,
patients were referred to a
psychology practice in association
with a pain clinic (Jones, Lookatch, &
Moore, 2015).
1. Cross-comparison study (2009), n= 48,
participants older than 18, Englishspeaking, and no evidence of altered
mental status (Moore, Jones,
Browder, Daffron, & Passik, 2009).
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Table 2
Opioid Risk Tool
(Webster & Webster, 2005)
Mark each box that applies Female
Family history of substance abuse
Alcohol
Illegal drugs
Rx drugs
Personal history of substance abuse
Alcohol
Illegal drugs
Rx drugs
Age between 16 – 45 years
History of preadolescent
sexual abuse
Psychological disease
ADD, OCD, bipolar,
schizophrenia
Depression
Scoring totals

Male
1
2
4

3
3
4

3
4
5
1
3

3
4
5
1
0

2

2

1

1

A score of 3 or lower indicates low risk for future opioid abuse, a score of 4 to 7 indicates moderate risk for
opioid abuse, and a score of 8 or higher indicates a high risk for opioid abuse.
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Table 3
SOAPP-R
(Butler et al., 2009)
Please answer the questions using the following scale:
0 = Never, 1 = Seldom, 2 = Sometimes, 3 = Often, 4 = Very Often
1. How often do you have mood swings?
2. How often have you felt a need for higher doses of medication
to treat your pain?
3. How often have you felt impatient with your doctors?
4. How often have you felt that things are just too overwhelming
that you can’t handle them?
5. How often is their tension in the home?
6. How often have you counted pain pills to see how many are
remaining?
7. How often have you been concerned that people will judge you
for taking pain medication?
8. How often do you feel bored?
9. How often have you taken more pain medication than you were
supposed to?
10. How often have you worried about being left alone?
11. How often have you felt a craving for medication?
12. How often have others expressed concern over your use of
medication?
13. How often have any of your close friends had a problem with
alcohol or drugs?
14. How often have others told you that you have a bad temper?
15. How often have you felt consumed by the need to get pain
medication?
16. How often have you run out of pain medication early?
17. How often have others kept you from getting what you deserve?
18. How often, in your lifetime, have you had legal problems or
been arrested?
19. How often have you attended an AA or NA meeting?
20. How often have you been in an argument that was so out of
control that someone got hurt?
21. How often have you been sexually abused?
22. How often have others suggested that you have a drug or alcohol
problem?
23. How often have you had to borrow pain medications from your
family or friends?
24. How often have you been treated for an alcohol or drug
problem?
Total

01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234
01234

A score of 9 or less indicates low risk, a score of 10-21 indicates moderate risk, and a score of 22 or more
indicates high risk for opiate misuse.
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Table 4
CDC Guidelines for Prescribing Opioids for Chronic Pain
(Dowell et al., 2016)
1. Nonpharmacological and nonopioid medications
are the preferred treatment for chronic pain; and
if used, opioids should be combined with these
therapies as appropriate.
2. Prior to beginning opioid therapy for chronic
pain, realistic goals for pain and control and
function should be established, in addition to
how therapy will be stopped if the risks
outweigh the benefits.
3. Known risks and realistic benefits should be
addressed prior to initiation of therapy as well as
periodically throughout.
4. Immediate-release opioids should be prescribed
for chronic pain, rather than extendedrelease/long-acting opioids.
5. PCPs should prescribe the lowest effect dose;
care should be taken when increasing to dosage
to >50 morphine milligram equivalents
(MME)/day and avoid increasing to >90
MME/day.
6. When prescribing for acute pain, less than three
days-worth of opioid medication is usually
sufficient, and no more than 7 days-worth
should be prescribed.

7. PCPs should assess benefits and harms of opioid
therapy at 1-4 weeks of starting opioid therapy,
every 3 months or more frequently if needed. If
benefits do not outweigh the risks, efforts
should be made to taper and discontinue
opioids.
8. PCPs should utilize strategies to minimize
opioid-associated risks, such as prescribing
naloxone for high-risk patients (history of
overdose or substance abuse disorder, high
opioid dosages, or concurrent benzodiazepine
use.
9. PCPs should consult the state prescription drugmonitoring program at a range of every three
months to every prescription, to check for
potential pharmaceutical combinations.
10. Urine drug testing to check for other controlled
substances/illicit drugs should be completed
prior to starting opioid therapy and periodically
throughout treatment.
11. PCPs should avoid prescribing opioid
medication with benzodiazepine medication
whenever possible.
12. For patients with opioid use disorder, PCPs
should offer medication-assisted treatment
(buprenorphine/methadone along with
behavioral therapies.)
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